These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1492230)

  • 1. New perspectives on the toxicity of etoposide.
    Kobayashi K; Ratain MJ
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):78-83. PubMed ID: 1492230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and long-term toxicity of etoposide.
    Kobayashi K; Ratain MJ
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S64-8. PubMed ID: 8070030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer.
    Bokemeyer C; Schmoll HJ; Kuczyk MA; Beyer J; Siegert W
    J Natl Cancer Inst; 1995 Jan; 87(1):58-60. PubMed ID: 7666466
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia.
    Felix CA; Winick NJ; Negrini M; Bowman WP; Croce CM; Lange BJ
    Cancer Res; 1993 Jul; 53(13):2954-6. PubMed ID: 8319201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study.
    Thompson DS; Hainsworth JD; Hande KR; Holzmer MC; Greco FA
    J Clin Oncol; 1993 Jul; 11(7):1322-8. PubMed ID: 8315429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy.
    Schwartsmann G; Sprinz E; Kromfield M; Kalakun L; Sander E; Prolla G; Di Leone L; Gerhardt L; Mans DR
    J Clin Oncol; 1997 May; 15(5):2118-24. PubMed ID: 9164226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epipodophyllotoxins and secondary leukaemia.
    Kumar L
    Lancet; 1993 Oct; 342(8875):819-20. PubMed ID: 8104269
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose etoposide with autologous bone marrow transplantation as initial treatment of small cell lung cancer--a negative report.
    Littlewood TJ; Bentley DP; Smith AP
    Eur J Respir Dis; 1986 May; 68(5):370-4. PubMed ID: 3015650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.
    Smith MA; Rubinstein L; Anderson JR; Arthur D; Catalano PJ; Freidlin B; Heyn R; Khayat A; Krailo M; Land VJ; Miser J; Shuster J; Vena D
    J Clin Oncol; 1999 Feb; 17(2):569-77. PubMed ID: 10080601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
    Pedersen-Bjergaard J; Philip P; Larsen SO; Andersson M; Daugaard G; Ersbøll J; Hansen SW; Hou-Jensen K; Nielsen D; Sigsgaard TC
    Leukemia; 1993 Dec; 7(12):1975-86. PubMed ID: 8255096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of etoposide in advanced prostate cancer.
    Trump DL; Loprinzi CL
    Cancer Treat Rep; 1984 Sep; 68(9):1195-6. PubMed ID: 6478456
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins.
    McLeod HL; Evans WE
    Cancer Surv; 1993; 17():253-68. PubMed ID: 8137343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias.
    Ellis M; Ravid M; Lishner M
    Leuk Lymphoma; 1993 Sep; 11(1-2):9-13. PubMed ID: 8220158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine.
    Laubenstein LJ; Krigel RL; Odajnyk CM; Hymes KB; Friedman-Kien A; Wernz JC; Muggia FM
    J Clin Oncol; 1984 Oct; 2(10):1115-20. PubMed ID: 6208343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.
    Kaul S; Srinivas NR; Igwemezie LN; Barbhaiya RH
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):15-22. PubMed ID: 8996571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Small cell lung cancer with acute monocytic leukemia after combined chemotherapy including etoposide].
    Tamada T; Kimura K; Tabata M; Ishimori S; Tsuburaya T; Hayashi M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 May; 35(5):577-82. PubMed ID: 9234639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling interpatient pharmacodynamic variability of etoposide.
    Mick R; Ratain MJ
    J Natl Cancer Inst; 1991 Nov; 83(21):1560-4. PubMed ID: 1960753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary acute promyelocytic leukemia in a child treated with epipodophyllotoxins.
    Lopez-Andrew JA; Ferrís J; Verdeguer A; Esquembre C; Senent ML; Castel V
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):384-6. PubMed ID: 7978063
    [No Abstract]   [Full Text] [Related]  

  • 20. Etoposide: an update.
    Fleming RA; Miller AA; Stewart CF
    Clin Pharm; 1989 Apr; 8(4):274-93. PubMed ID: 2653712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.